In Brief: Saline breast implant studies
This article was originally published in The Gray Sheet
Executive Summary
Saline breast implant studies: As of Sept. 30, manufacturers Mentor and McGhan have enrolled 608 and 1329 patients, respectively, in a one-year prospective clinical trial on saline breast implants, according to figures presented by FDA device center Deputy Director for Regulations and Policy Joseph Levitt at the American Society of Plastic and Reconstructive Surgeons' annual meeting Oct. 7 in Montreal. The trials, scheduled to be completed in 1997, are expected to enroll approximately 3,000 patients by December. Mentor also has enrolled a total of 1599 patients (1268 augmentation/331 reconstruction) for a three-year prospective trial on the implants designed to address overall safety and quality of life issues. McGhan has enrolled 925 patients (820 augmentation/105 reconstruction) in the three-year trial...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.